IceCure Medical is an Israeli company that develops and markets minimally invasive cryoablation therapies for women’s health and other areas. Our proprietary ProSense™ system provides minimally invasive, in-office definitive treatment for breast tumors, both benign and breast cancer.
IceCure sells its products in the U.S. Among our U.S clients are breast centers in reputable institutions as well as private clinics operated by breast surgeons and radiologists. In other geographies, IceCure uses specialized distributors that provide clinical and technical sales support in Asia and Europe.
IceCure has FDA and CE clearances for broad benign and malignant indications. The company is also in advanced regulatory process in China with the CFDA as well as other Asian and South American countries. Due to its unique and innovative technology, IceCure participate in several clinical studies for treatment of other indications such as lung cancer, Kidney cancer and breast cancer.
With the global trend of taking procedures from the operating room to the office environment and decreasing their costs, IceCure’s innovation brings the future to the present!
During Jan. 7 to 11, 2019 Tlalit Bussi Tel-Tzure (BD & Marketing Director, IceCure Medical Ltd.) would be visiting New Delhi, Gurgaon, Chennai and Mumbai to explore opportunities to collaborate.
For more information, please contact: